TFAP2A and Its Role in Lung Cancer Progression
Author Information
Author(s): Wang Ding-Guo, Gao Jian, Wang Jing, Li Kun-Chao, Wu Zhi-Bo, Liao Zhong-Min, Wu Yong-Bing
Primary Institution: The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
Hypothesis
TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway.
Conclusion
High levels of TFAP2A are associated with poor prognosis in NSCLC patients and promote tumor growth and resistance to therapy.
Supporting Evidence
- TFAP2A levels were significantly greater in tumor tissues than para-tumor tissues.
- High expression of TFAP2A was associated with poor prognosis in NSCLC patients.
- TFAP2A overexpression promoted NSCLC progression both in vivo and in vitro.
- TFAP2A can bind to the promoter region of ESR2, activating its transcription.
- The combination of PHTPP and osimertinib had a synergistic effect on suppressing tumor growth.
Takeaway
This study found that a protein called TFAP2A helps lung cancer grow and makes it harder to treat, so targeting it could help patients.
Methodology
The study involved analyzing TFAP2A expression in tumor and para-tumor tissues, conducting in vitro and in vivo experiments, and using bioinformatics to identify pathways.
Potential Biases
Potential biases may arise from the selection of patient samples and the reliance on specific databases for data analysis.
Limitations
The study primarily focused on TFAP2A and ESR2 without exploring other potential factors influencing NSCLC progression.
Participant Demographics
Patients with non-small cell lung cancer, with a sample size of 102 paired tumor and para-tumor tissues.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website